Additional file 1_ List of Included References

Studies included in the systematic review (by year of publication)

1991-1995

1996-2000


28. Caro JJ, Huybrechts KF, De Backer G, De Bacquer D, Closon MC. Are the WOSCOPS clinical and economic findings generalizable to other populations? A case study for Belgium. The

2001-2005


38. Scuffham PA, Chaplin S. An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK. Pharmaco economics. 2004;22(8):525-35.


2006-2011


75. Michailov GV, Davies GM, Krobot KJ. Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany. Eur J Health Econ. 2011 Apr 5. [Epub ahead of print]